Results 241 to 250 of about 114,065 (338)

Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People With Chronic Lymphocytic Leukaemia. [PDF]

EJHaem
Miles EE, Nicol JL, Fowler H, Roberts A, Hulton AT, Jeary C, Walewska R, Iyengar S, Hanson ED, CLL Support Association, Sitlinger A, Bartlett DB.   +11 more
europepmc   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

Effects of sample age and storage temperature on the flow cytometric diagnosis of chronic lymphocytic leukaemia in South Africa. [PDF]

Afr J Lab Med
Grobler SM, van Marle AC.
europepmc   +1 more source

Postoperative Care and Management in Pediatric Hematology‐Oncology Patients

European Journal of Haematology, EarlyView.
ABSTRACT Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others.
Shachi Srivatsa, Sara A. Mansfield
wiley   +1 more source

Characterisation of Cytotoxicity-Related Receptors on γδ T Cells in Chronic Lymphocytic Leukaemia. [PDF]

Cells
Zarobkiewicz M, Lehman N, Morawska-Michalska I, Michalski A, Kowalska W, Szymańska A, Tomczak W, Bojarska-Junak A.   +7 more
europepmc   +1 more source

Transition Into Clinical Routine and Survival Outcomes of BCL2‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

European Journal of Haematology, EarlyView.
ABSTRACT Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence.
Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Dörfel, Jörg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al‐Sawaf, Petra Langerbeins, Paula Cramer, Michael Hallek, Barbara Eichhorst, Kirsten Fischer, Anna Fink   +16 more
wiley   +1 more source

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. [PDF]

Intern Med J
Anderson MA, Awan FT, Berkahn L, Crassini K, Lee HP, Marlton P, Mulligan SP, Nolan M, Tam C, Sverdlov AL.   +9 more
europepmc   +1 more source